{"denoms":[{"counts":[{"groupId":"BG000","value":"40"}],"units":"Participants"}],"groups":[{"description":"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.\n\nCyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.\n\nDays 2 \\& 3: Aprepitant 80 mg once daily in the morning.\n\nAprepitant: Aprepitant 80mg once daily in the morning on days 2 and 3\n\nCyclophosphamide: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes\n\nDexamethasone: Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.\n\nGranisetron hydrochloride: Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.","id":"BG000","title":"Aprepitant, Dexamethasone, Cytoxan & Kytril"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"40"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Patients who received all doses of the study drug were considered evaluable patients."}